Derek Archila
Stock Analyst at Wells Fargo
(3.95)
# 619
Out of 5,024 analysts
187
Total ratings
52.46%
Success rate
10.13%
Average return
Main Sectors:
Stocks Rated by Derek Archila
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLS Apellis Pharmaceuticals | Upgrades: Overweight | $29 → $32 | $25.40 | +25.98% | 13 | Oct 15, 2025 | |
| KYTX Kyverna Therapeutics | Maintains: Overweight | $24 → $27 | $7.05 | +282.98% | 2 | Oct 8, 2025 | |
| CCCC C4 Therapeutics | Maintains: Overweight | $5 → $10 | $2.65 | +277.36% | 6 | Sep 23, 2025 | |
| ATYR aTyr Pharma | Downgrades: Equal-Weight | $25 → $1 | $1.06 | -5.21% | 3 | Sep 16, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Overweight | $44 → $38 | $27.00 | +40.74% | 4 | Aug 20, 2025 | |
| SLNO Soleno Therapeutics | Initiates: Overweight | $123 | $67.19 | +83.06% | 1 | Aug 20, 2025 | |
| STRO Sutro Biopharma | Maintains: Equal-Weight | $4 → $3 | $0.81 | +271.56% | 1 | Aug 12, 2025 | |
| CABA Cabaletta Bio | Maintains: Equal-Weight | $3 → $2 | $2.92 | -31.51% | 11 | Aug 8, 2025 | |
| ASND Ascendis Pharma | Maintains: Overweight | $289 → $295 | $209.89 | +40.55% | 14 | Aug 8, 2025 | |
| ZNTL Zentalis Pharmaceuticals | Maintains: Equal-Weight | $6 → $5 | $1.63 | +206.75% | 5 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $27 → $26 | $22.23 | +16.96% | 2 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $19 → $16 | $9.78 | +63.60% | 7 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $67 → $89 | $90.93 | -2.12% | 9 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $741 → $756 | $825.02 | -8.37% | 12 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $4.72 | +260.17% | 1 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $91 → $129 | $111.84 | +15.34% | 6 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $57 → $53 | $62.82 | -15.63% | 8 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $18 | $23.33 | -22.83% | 4 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $25 | $10.69 | +133.86% | 5 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $10 | $10.80 | -7.41% | 5 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $15 | $3.55 | +322.54% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $36 | $39.38 | -8.58% | 3 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $51 | $34.22 | +49.04% | 3 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $14 | $19.00 | -26.32% | 5 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $9 | $4.20 | +114.29% | 11 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $45 | $17.81 | +152.67% | 9 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $11 | $3.88 | +183.87% | 4 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $10 | $3.15 | +217.97% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $37 → $20 | $2.56 | +682.78% | 7 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $5.19 | +246.82% | 1 | Aug 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $4.23 | - | 1 | Jul 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $298 → $193 | $34.96 | +452.06% | 1 | Jul 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $61 → $41 | $68.19 | -39.87% | 1 | Apr 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $480 → $160 | $20.07 | +697.41% | 3 | Mar 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $180 → $60 | $17.38 | +245.22% | 3 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $29 | $5.38 | +439.03% | 4 | Dec 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $50 | $1.34 | +3,645.32% | 2 | Jun 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $51 | $17.41 | +192.94% | 1 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $88 | $21.32 | +312.76% | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $23.09 | - | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $19.87 | - | 2 | Aug 3, 2017 |
Apellis Pharmaceuticals
Oct 15, 2025
Upgrades: Overweight
Price Target: $29 → $32
Current: $25.40
Upside: +25.98%
Kyverna Therapeutics
Oct 8, 2025
Maintains: Overweight
Price Target: $24 → $27
Current: $7.05
Upside: +282.98%
C4 Therapeutics
Sep 23, 2025
Maintains: Overweight
Price Target: $5 → $10
Current: $2.65
Upside: +277.36%
aTyr Pharma
Sep 16, 2025
Downgrades: Equal-Weight
Price Target: $25 → $1
Current: $1.06
Upside: -5.21%
Celldex Therapeutics
Aug 20, 2025
Maintains: Overweight
Price Target: $44 → $38
Current: $27.00
Upside: +40.74%
Soleno Therapeutics
Aug 20, 2025
Initiates: Overweight
Price Target: $123
Current: $67.19
Upside: +83.06%
Sutro Biopharma
Aug 12, 2025
Maintains: Equal-Weight
Price Target: $4 → $3
Current: $0.81
Upside: +271.56%
Cabaletta Bio
Aug 8, 2025
Maintains: Equal-Weight
Price Target: $3 → $2
Current: $2.92
Upside: -31.51%
Ascendis Pharma
Aug 8, 2025
Maintains: Overweight
Price Target: $289 → $295
Current: $209.89
Upside: +40.55%
Zentalis Pharmaceuticals
Aug 7, 2025
Maintains: Equal-Weight
Price Target: $6 → $5
Current: $1.63
Upside: +206.75%
Aug 7, 2025
Maintains: Equal-Weight
Price Target: $27 → $26
Current: $22.23
Upside: +16.96%
Aug 7, 2025
Maintains: Overweight
Price Target: $19 → $16
Current: $9.78
Upside: +63.60%
Aug 6, 2025
Upgrades: Overweight
Price Target: $67 → $89
Current: $90.93
Upside: -2.12%
Jul 31, 2025
Maintains: Overweight
Price Target: $741 → $756
Current: $825.02
Upside: -8.37%
Jul 25, 2025
Initiates: Overweight
Price Target: $17
Current: $4.72
Upside: +260.17%
Jul 10, 2025
Maintains: Overweight
Price Target: $91 → $129
Current: $111.84
Upside: +15.34%
Jun 26, 2025
Maintains: Overweight
Price Target: $57 → $53
Current: $62.82
Upside: -15.63%
May 16, 2025
Maintains: Equal-Weight
Price Target: $11 → $18
Current: $23.33
Upside: -22.83%
Apr 9, 2025
Maintains: Overweight
Price Target: $32 → $25
Current: $10.69
Upside: +133.86%
Mar 21, 2025
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $10.80
Upside: -7.41%
Mar 12, 2025
Maintains: Equal-Weight
Price Target: $16 → $15
Current: $3.55
Upside: +322.54%
Feb 24, 2025
Downgrades: Equal-Weight
Price Target: $36
Current: $39.38
Upside: -8.58%
Feb 13, 2025
Maintains: Overweight
Price Target: $40 → $51
Current: $34.22
Upside: +49.04%
Dec 19, 2024
Maintains: Equal-Weight
Price Target: $12 → $14
Current: $19.00
Upside: -26.32%
Dec 19, 2024
Maintains: Equal-Weight
Price Target: $11 → $9
Current: $4.20
Upside: +114.29%
Dec 19, 2024
Maintains: Overweight
Price Target: $47 → $45
Current: $17.81
Upside: +152.67%
Aug 12, 2024
Maintains: Overweight
Price Target: $16 → $11
Current: $3.88
Upside: +183.87%
May 15, 2024
Maintains: Overweight
Price Target: $12 → $10
Current: $3.15
Upside: +217.97%
May 5, 2021
Downgrades: Hold
Price Target: $37 → $20
Current: $2.56
Upside: +682.78%
Aug 4, 2020
Initiates: Buy
Price Target: $18
Current: $5.19
Upside: +246.82%
Jul 23, 2020
Upgrades: Buy
Price Target: n/a
Current: $4.23
Upside: -
Jul 10, 2020
Downgrades: Hold
Price Target: $298 → $193
Current: $34.96
Upside: +452.06%
Apr 15, 2020
Reiterates: Buy
Price Target: $61 → $41
Current: $68.19
Upside: -39.87%
Mar 31, 2020
Maintains: Hold
Price Target: $480 → $160
Current: $20.07
Upside: +697.41%
Mar 17, 2020
Downgrades: Hold
Price Target: $180 → $60
Current: $17.38
Upside: +245.22%
Dec 11, 2018
Downgrades: Perform
Price Target: $29
Current: $5.38
Upside: +439.03%
Jun 22, 2018
Maintains: Outperform
Price Target: $34 → $50
Current: $1.34
Upside: +3,645.32%
Nov 15, 2017
Maintains: Outperform
Price Target: $32 → $51
Current: $17.41
Upside: +192.94%
Sep 7, 2017
Initiates: Outperform
Price Target: $88
Current: $21.32
Upside: +312.76%
Sep 7, 2017
Initiates: Market Perform
Price Target: n/a
Current: $23.09
Upside: -
Aug 3, 2017
Downgrades: Perform
Price Target: n/a
Current: $19.87
Upside: -